TriSalus Life Sciences, Inc.
TLSI
$5.10
$0.173.45%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -91.32% | 21.44% | 71.64% | -61.00% | 69.00% |
Total Depreciation and Amortization | -14.95% | -1.71% | -0.52% | 8.33% | 29.33% |
Total Amortization of Deferred Charges | -3.75% | -- | -- | -- | -- |
Total Other Non-Cash Items | 160.99% | 46.20% | -84.07% | 64.05% | -220.30% |
Change in Net Operating Assets | 78.24% | 431.06% | -88.03% | 31.97% | -426.84% |
Cash from Operations | 45.46% | 58.60% | 37.81% | 49.93% | -45.32% |
Capital Expenditure | 255.00% | -1,042.42% | 86.56% | 5.06% | -93.55% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | 255.00% | -981.82% | 86.56% | 84.80% | -100.00% |
Total Debt Issued | -100.00% | -- | -- | -- | -- |
Total Debt Repaid | 95.24% | -222.73% | 13.64% | 0.00% | 0.00% |
Issuance of Common Stock | 517.33% | -91.14% | 3,444.71% | 20,775.00% | 22,443.75% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 40.26% | -- | 100.00% | -100.00% | -- |
Cash from Financing | -20.30% | 209.92% | 6,862.79% | -85.53% | 305.95% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 7.83% | 157.32% | 70.93% | -129.71% | 536.99% |